Description
Incyte Corporation’s $450 Million Opzelura Franchise Unlocks A New Growth Engine!
Incyte Corporation’s second quarter of 2026 performance reflects significant progress in diversifying its revenue base beyond its cornerstone product, Jakafi, while advancing multiple late-stage clinical programs across hematology, oncology, and immunology/inflammation franchises. Total revenue increased 38% year-over-year to $1.67 billion, with total net sales of $1.49 billion, marking a 40% increase. Excluding a one-time noncash benefit of $246 million from a CMS settlement related to Medicaid rebate litigation impacting Opzelura, net sales grew 17%. Jakafi sales rose 7% to $817 million, driven by increased prescription demand across all indications, with polycythemia vera emerging as the largest growth contributor. The launch of Jakafi XR has gained meaningful formulary coverage and initial sales, with adoption expected to grow through 2027. Incyte’s core business excluding Jakafi demonstrated robust growth, with sales up 127% year-over-year to $671 million, or 44% excluding the CMS settlement benefit.
